ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Wyden Hearing On Taxol Agreements Mangles Facts In Attempt To Protect ‘Public Interest’

August 9, 1991

Study Links Native American Ancestry to Leukemia Relapse

February 25, 2011

NCAB Votes Down Dietary Fat Study In women; Proposal highly Recommended By Study Section

September 29, 1989

In Brief: NCAB ask Force Supports Group-Led Data and Safety Monitoring Committees

August 19, 1994

Funding Opportunities.

July 19, 2002

Hawaiian Have Highest Cancer Rate In U.S.

April 29, 1983